EXEL (Exelixis) Cyclically Adjusted Revenue per Share: $5.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EXEL Exelixis Inc EXEL
88 GF Score
Price $53.69
GF Value $45.73
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Cyclically Adjusted Revenue per Share?

Exelixis EXEL -1.31% 88 Cyclically Adjusted Revenue per Share is $5.27 as of Jun. 2026. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Exelixis's adjusted revenue per share for the three months ended in Jun. 2026 was $2.421. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $5.27 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Exelixis's average Cyclically Adjusted Revenue Growth Rate was 24.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 25.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Exelixis was 28.80% per year. The lowest was -6.20% per year. And the median was 7.70% per year.

As of today (2026-08-20), Exelixis's current stock price is $53.69. Exelixis's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $5.27. Exelixis's Cyclically Adjusted PS Ratio of today is 10.19.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exelixis was 30.70. The lowest was 6.49. And the median was 11.73.


Exelixis  (NAS:EXEL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exelixis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=53.69/5.27
=10.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exelixis was 30.70. The lowest was 6.49. And the median was 11.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Exelixis Cyclically Adjusted Revenue per Share Related Terms


Exelixis Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Exelixis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Cyclically Adjusted Revenue per Share Chart

Exelixis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 2.35 2.98 3.78 4.68

Exelixis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 4.48 4.68 4.99 5.27

EXEL vs MDGL, AXSM, ARWR: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PS Ratio falls into.


EXEL
88GF Score
Exelixis Inc EXEL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exelixis's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.421/333.9520*333.9520
=2.421

Current CPI (Jun. 2026) = 333.9520.

Exelixis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.243 241.428 0.336
201612 0.269 241.432 0.372
201703 0.261 243.801 0.358
201706 0.318 244.955 0.434
201709 0.487 246.819 0.659
201712 0.383 246.524 0.519
201803 0.681 249.554 0.911
201806 0.596 251.989 0.790
201809 0.722 252.439 0.955
201812 0.734 251.233 0.976
201903 0.685 254.202 0.900
201906 0.763 256.143 0.995
201909 0.861 256.759 1.120
201912 0.763 256.974 0.992
202003 0.718 258.115 0.929
202006 0.816 257.797 1.057
202009 0.748 260.280 0.960
202012 0.845 260.474 1.083
202103 0.841 264.877 1.060
202106 1.193 271.696 1.466
202109 1.020 274.310 1.242
202112 1.396 278.802 1.672
202203 1.101 287.504 1.279
202206 1.291 296.311 1.455
202209 1.267 296.808 1.426
202212 1.305 296.797 1.468
202303 1.253 301.836 1.386
202306 1.436 305.109 1.572
202309 1.478 307.789 1.604
202312 1.532 306.746 1.668
202403 1.392 312.332 1.488
202406 2.167 314.175 2.303
202409 1.851 315.301 1.960
202412 1.931 315.605 2.043
202503 1.927 319.799 2.012
202506 1.998 322.561 2.069
202509 2.146 324.800 2.206
202512 2.166 324.054 2.232
202603 2.285 330.213 2.311
202606 2.421 333.952 2.421

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $5.27 mean?
Exelixis (EXEL) has a Cyclically Adjusted Revenue per Share of $5.27 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Exelixis and its competitors.
Is Exelixis' Cyclically Adjusted Revenue per Share too high?
Exelixis' current Cyclically Adjusted Revenue per Share is $5.27. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Cyclically Adjusted Revenue per Share compare to MDGL and AXSM?
Exelixis' Cyclically Adjusted Revenue per Share of $5.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Exelixis and its competitors. Exelixis's current Cyclically Adjusted Revenue per Share is $5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.69 — trading 17.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $5.27. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Exelixis (EXEL), the current Cyclically Adjusted Revenue per Share is $5.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (EXEL) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of $53.69 is trading 17.4% above its estimated GF Value™ of $45.73. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for EXEL:

  • Cyclically Adjusted Revenue per Share: $5.27
  • GF Value™: $45.73 vs. price of $53.69 (17.4% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score

Get the complete analysis for EXEL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.69
Price
$45.73
GF Value